FY2025 · ended Dec 31, 2025 · Revenue $236.20M, +47.5% YoY · Filed Feb 26, 2026
Akebia Therapeutics, Inc. (AKBA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $236.2 million and a net loss of $5.3 million. Free cash flow was $67.7 million. As of Jun 30, 2026 it held $155.5 million in cash and investments and $54.9 million in total debt.
Revenue (TTM)
$219.06M
+7.5% vs year-ago TTM
Net income (TTM)
$-29.67M
+18.7% vs year-ago TTM
Operating cash flow (TTM)
$41.55M
+1829.2% vs year-ago TTM
Free cash flow (TTM)
$40.26M
+1678.4% vs year-ago TTM
EPS (TTM)
$-0.11
+27.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
267.88M
+13.4% vs prior year
Net cash
$100.65M
as of Jun 30, 2026
Operating margin
-6.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKBA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1517022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M | -$264.5M |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$282.0M |
| Diluted EPS | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 |
| Operating cash flow | $68.0M | -$40.7M | -$23.4M | -$73.2M | -$253.0M |
| Free cash flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | -$253.0M |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $529.3M |
| Total liabilities | $344.0M | $269.9M | $272.3M | $350.8M | $455.3M |
| Stockholders' equity | $32.6M | -$49.2M | -$30.6M | $5.2M | $74.0M |
| Cash and investments | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M |
| Total debt | $51.8M | $47.6M | $48.1M | $99.8M | $136.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 23, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 14, 2026 | Oct 7, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 17, 2026 |
All 884 Akebia Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.